Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center

Austin, John R.; Cebrun, Hazel; Kershisnik, Mathew M.; El‐Naggar, Adel K.; Garden, Adam S.; DeMonte, Franco; Ginsberg, Lawrence E.; Lippman, Scott M.; Goepfert, Helmuth

doi:10.1055/s-2008-1058907

Cited by 40 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall survival at 5 years could be extracted from 25 studies; the mean was 45% (SD 22), with extremes of 86% 58 and zero. 57 Disease-free survival at 2 years was found in 17 studies, 2,43,[54][55][56][57][58]60,62,65,66,[68][69][70][71]73,78 that at 3 years in 20 reports 4,6,8,43,[54][55][56][57][58]60,62,65,66,[68][69][70][71][72][73]78 and that at 5 years in 24 publications. 2,4,6,8,43,[54][55][56][57][58][60][61]…”

Section: Resultsmentioning

confidence: 99%

“…The 26 studies 2,[4][5][6]8,43,[54][55][56][57][58][60][61][62][63][64][65][66][68][69][70][71][72][73]77,78 reported on 390 patients with ENB. Overall survival at 5 years could be extracted from 25 studies; the mean was 45% (SD 22), with extremes of 86% 58 and zero.…”

Section: Resultsmentioning

confidence: 99%

“…2,4,61,63 The theoretical advantage that preoperative radiotherapy will reduce an unresectable tumour to a resectable size has never been clearly demonstrated. 64 Standard radiotherapeutic techniques include external megavoltage beam and a three-field technique; an anterior port is combined with wedged lateral fields to provide a homogeneous dose distribution.…”

Section: Treatmentmentioning

confidence: 99%

“…Therefore, patients given primary or preoperative radiotherapy can be staged as reliably as those who are candidates for surgery. Although this classification system has gained popularity, [4][5][6] various attempts have been made to modify the Kadish system for ENB. 7,8 Within the past decade, there has been progress in identifying the origin of ENB, which should lead to more precise diagnosis.…”

Section: Lancet Oncol 2001; 2: 683-90mentioning

confidence: 99%

“…These were supplemented by another 19 relevant publications found in references cited. 4,[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] The studies were divided into three types, according to their principal objectives: origin and aetiology of ENB, 9,11,15,[17][18][19]21,24,[27][28][29][30][31][32][33][34][35][36][37][38][39][40] histopathological diagnosis; 10,[12][13][14]23,37,[41][42][43][44]…”

Section: Search Strategy and Selection Criteriamentioning

confidence: 99%

See 4 more Smart Citations

Esthesioneuroblastoma: a meta-analysis and review

Dulguerov

Allal

Calcaterra

2001

The Lancet Oncology

541

698

View full text Add to dashboard Cite

Our objective was to review recent developments in diagnosis, staging, and treatment of esthesioneuroblastoma (ENB). A meta-analysis of publications between 1990 and 2000 was carried out, and studies were classified according to their main subject: origin/aetiology of ENB, histopathological diagnosis, and treatment. Data so far point to the basal progenitor cells of the olfactory epithelium as the origin of ENB. Histopathological diagnosis remains difficult and is based on results of antigen expression detected through a panel of antibodies by immunohistochemistry. RT-PCR of HASH expression could be a specific marker of ENB. Overall and disease-free survival at 5 years averaged 45% (SD 22) and 41% (SD 21) in the studies included in the meta-analysis. Survival in Hyams' grades I-II was 56% (SD 20) compared with 25% (SD 20) in grades III-IV (odds ratio 6.2). In patients with metastases in cervical lymph nodes (on average 5% of the total) survival was 29%, compared with 64% for patients with N0 disease (odds ratio 5.1). Survival according to treatment modalities was 65% for surgery plus radiotherapy, 51% for radiotherapy and chemotherapy, 48% for surgery, 47% for surgery plus radiotherapy and chemotherapy, and 37% for radiotherapy alone. The histopathological grading according to Hyams and the presence of cervical lymph-node metastases emerged as prognostic factors. A combination of surgery and radiotherapy seems to be the optimum approach to treatment. The exact role of chemotherapy in treatment protocols is still unclear. The role of elective neck dissection is unclear

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Section: Lancet Oncol 2001; 2: 683-90mentioning

confidence: 99%

Section: Search Strategy and Selection Criteriamentioning

confidence: 99%

See 3 more Smart Citations

Esthesioneuroblastoma: a meta-analysis and review

Dulguerov

Allal

Calcaterra

2001

The Lancet Oncology

541

698

View full text Add to dashboard Cite

show abstract

A New Classification for Malignant Tumors Involving the Anterior Skull Base

Cantù

Solero²,

Mariani

et al. 1999

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma

Kiyota

Tahara

Fujii

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND The efficacy and safety of chemotherapy with irinotecan plus docetaxel were retrospectively evaluated for olfactory neuroblastoma. METHODS Twelve patients with histologically proven advanced or metastatic olfactory neuroblastoma were treated with chemotherapy with irinotecan plus docetaxel at the study institution between 2001 and 2005. Of these, 7 patients with locoregional disease and no prior radiotherapy received irinotecan plus docetaxel followed by definitive radiotherapy, 1 with photon radiotherapy and 6 with proton radiotherapy, whereas 3 patients with distant metastases and 2 with locoregional disease who had received prior radiotherapy received irinotecan plus docetaxel only. RESULTS The most common toxicities of ≥grade 3 among the 12 patients receiving irinotecan plus docetaxel were leukopenia (33%), neutropenia (50%), febrile neutropenia (8%), and diarrhea (25%), all of which were manageable. Partial response was achieved in 3 patients, giving an overall response rate of 25%. The response rate was higher in patients aged <50 years (3 of 4 patients) compared with those aged >50 years (0 of 8 patients) (P = .018). With a median follow‐up period of 22.2 months, the median progression‐free survival and overall survival were 13.6 months and 36.6 months, respectively. Of the 7 patients with locoregional disease also receiving definitive radiotherapy, the 2‐year survival rate was 100% and 6 patients were alive at the time of last follow‐up. CONCLUSIONS Chemotherapy for olfactory neuroblastoma with irinotecan plus docetaxel is safe and manageable. Patients aged <50 years may be sensitive to chemotherapy. Induction chemotherapy followed by definitive radiotherapy may represent a promising option for patients with locally advanced olfactory neuroblastoma. Cancer 2008. © 2008 American Cancer Society.

show abstract

Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center

Cited by 40 publications

References 12 publications

Esthesioneuroblastoma: a meta-analysis and review

Esthesioneuroblastoma: a meta-analysis and review

A New Classification for Malignant Tumors Involving the Anterior Skull Base

Nonplatinum‐based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma

Contact Info

Product

Resources

About